Drug
Durvalumab Tremelimumab Metronomic Vinorelbine
Durvalumab Tremelimumab Metronomic Vinorelbine: highest development phase Phase 1/2, developed by Pierre Fabre. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Pierre Fabre
Trials
| Drug | Phase | Indication |
|---|---|---|
| Durvalumab + Tremelimumab + metronomic Vinorelbine NCT03518606 | Phase 1/2 | Advanced Solid Tumours |
Latest
No recent events.
Follow Durvalumab Tremelimumab Metronomic Vinorelbine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.